Stephen Husbands,

Ph.D.

Dr Husbands is currently Professor, Department of Life Sciences, University of Bath, UK. He is a Fellow of the Royal Society of Chemistry and a Member of the Advisory Council on the Misuse of Drugs (UK). As author of over 150 peer-reviewed scientific papers, he is a recognised expert and researcher in the medicinal chemistry of CNS active drugs, particularly with respect to compounds targeting the opioid system.

His research has been concerned with the development of ligands that bind to multiple opioid receptors, but with defined efficacy at each receptor and with the design of ligands with extended duration of action. These include some of PPL’s compounds.

Recently he has engaged in projects evaluating, both qualitatively and quantitatively, street drugs provided by the local police, prisons and charities, with a particular interest in hard-to-detect and rapidly evolving classes of drugs, such as the synthetic cannabinoids, benzodiazepines and synthetic opioids.

Dr Husbands’ projects are all highly collaborative and run in collaboration with colleagues around the world, but particularly the US, and in partnership with industry. Steve holds a B.Sc and Ph.D from the University of Strathclyde, Glasgow and had postdoc positions in medicinal chemistry relating to drug use disorders at the University of Bristol (UK) and at the National Institute on Drug Abuse (NIDA) in Baltimore.

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.